Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas

Liu, Shifeng; Lu, Peng; Zhang, Kaixian; Li, Wei; Zhang, Hao; Luan, Ying; Li, Peishun

doi:10.1186/s12885-020-07086-8

Cited by 12 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Iodine-125 seeds were implanted, as we previously reported [ 12 ]. Briefly, patients were safely fixed on the CT bed with a negative pressure vacuum pad.…”

Section: Methodsmentioning

confidence: 99%

“…Based on these characteristics, local treatment with 125 I is possible. Brachytherapy with iodine-125 seeds offered a safe and effective local treatment option for patients, including glioma in the eloquent brain [ 9 – 12 ]. Furthermore, 125 I brachytherapy showed advantages in tumor shrinkage as the 125 I seeds were inserted into the tumors, continuously releasing γ rays.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background A more extensive surgical resection of glioma contributes to improved overall survival (OS) and progression-free survival (PFS). However, some patients miss the chance of surgical resection when the tumor involves critical structures. Purpose The present study aimed to assess the feasibility of neoadjuvant 125I brachytherapy followed by total gross resection for initially inoperable glioma. Methods Six patients diagnosed with inoperable glioma due to invasion of eloquent areas, bihemispheric diffusion, or large tumor volume received 125I brachytherapy. Surgical resection was performed when the tumor shrank, allowing a safe resection, assessed by the neurosurgeons. Patients were followed up after surgery. Results Shrinkage of the tumor after adjuvant 125I brachytherapy enabled a total gross resection of all six patients. Four patients were still alive at the last follow-up, with the longest survival time of more than 50 months, two of which returned to everyday life with a KPS of 100. Another two patients had neurological injuries with KPSs of 80 and 50, respectively. One patient with grade II glioma died 34 months, and another with grade IV glioma died 40 months after the combined therapy. Conclusions In the present study, the results demonstrated that 125I brachytherapy enabled a complete resection of patients with initially unresectable gliomas. 125I brachytherapy may offer a proper neoadjuvant therapy method for glioma.

show abstract

“…Iodine-125 seeds were implanted, as we previously reported [ 12 ]. Briefly, patients were safely fixed on the CT bed with a negative pressure vacuum pad.…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Iodine-125 seeds were implanted as we previously reported [11]. Brie y, patients were xed on the CT bed safely with a negative pressure vacuum pad.…”

Section: Iodine-125 Implantationmentioning

confidence: 99%

“…Based on the characteristics, the local treatment with 125 I is possible. Brachytherapy with iodine-125 seeds offered a safe and effective local treatment option for patients, including glioma located in the eloquent brain [8][9][10][11]. Furthermore, 125 I brachytherapy showed advantages on the tumor shrinkage as the 125 I seeds were inserted within the tumors, continuously releasing γ rays.…”

Section: Introductionmentioning

confidence: 99%

Effect of Neoadjuvant Iodine-125 Brachytherapy Upon Resection of Glioma

Liu

Jiang

Zhang

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: A more extensive surgical resection of glioma contributes to improved overall survival (OS) and progression-free survival (PFS). However, some of the patients lost the chance of surgical resection when the tumor involves critical structures. Purpose: The present study aimed to assess the feasibility of neoadjuvant 125I brachytherapy followed by total gross resection for initially inoperable glioma.Methods:Six patients diagnosed with inoperable glioma due to invasion of eloquent areas, bi-hemispheric diffusion, or large tumor volume received 125I brachytherapy. Surgical resection was performed when the tumor shrank, allowing a safe resection, assessed by the neurosurgeons. Patients were followed up after surgery.Results:Tumor shrinkage after adjuvant 125I brachytherapy enabled a total gross resection of all six patients. Four patients were still alive at the last follow-up, with the longest survival time of more than 50 months, two of which returned to a normal life with the KPS of 100. Another two patients got a neurological injury with the KPS of 80 and 50, respectively. One patient with grade Ⅱ glioma died 34 months, and another patient with grade Ⅳ glioma died 40 months later after the combined therapy.Conclusions: In the present study, the results demonstrated that 125I brachytherapy enabled a complete resection of patients with initially unresectable gliomas. 125I brachytherapy may offer a proper neoadjuvant therapy method for glioma.

show abstract

“…Therefore, a need to optimize radiation protocols assumes very high significance, which in turn necessitates accurate brain dosimetry. Iodine-125 ( 125 I) brachytherapy has been applied to brain tumors for almost four decades [ 2 – 5 ]. At present, the permanent implantation of 125 I seeds remains the preferred technique for tumors in any location within the brain [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

CT-MR Image Fusion for Post-Implant Dosimetry Analysis in Brain Tumor Seed Implantation- a Preliminary Study

et al. 2022

View full text Add to dashboard Cite

Purpose. To calculate and evaluate postimplant dosimetry (PID) with CT-MR fusion technique after brain tumor brachytherapy and compare the result with CT-based PID. Methods and Materials. 16 brain tumor patients received MR-guided intervention with Iodine-125 (125I) seed implantation entered this preliminary study for PID evaluation. Registration and fusion of CT and MR images of the same patients were performed one day after operation. Seeds identification and targets delineation were carried out on CT, MR, and CT-MR fusion images, each. The number and location of seeds on MR or CT- MR fusion images were compared with those of actually implanted seeds. Clinical target volume (CTV) and dosimetric parameters such as %D90, %V100 and external V100 were measured and calculated. In addition, the correlation of the fusion to CT CTV ratio and other factors were analyzed. Results. The numbers of fusion seeds were not significantly different compared with reference seeds (t =1.76, p >0.05). The difference between reference seeds numbers and truly extracted MR seeds numbers was statistically significant (t =3.91, p <0.05). All dosimetric parameters showed significant differences between the two techniques (p <0.05). The mean CTV delineated on fusion images was 34.3 ± 33.6, smaller than that on CT images. The mean values of external V100, %V100 and %D90 on fusion images were larger than those on CT images. Correlation analysis showed that the fusion-CT V100 ratio was positively and significantly correlated with the fusion-CT volume ratio. Conclusions. This preliminary study indicated that CT-MR fusion-based PID exhibited good accuracy for 125I brain tumor brachytherapy dosimetry when compared to CT-based PID and merits further research to establish best-outcome protocols.

show abstract

Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas

Cited by 12 publications

References 25 publications

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma

Effect of Neoadjuvant Iodine-125 Brachytherapy Upon Resection of Glioma

CT-MR Image Fusion for Post-Implant Dosimetry Analysis in Brain Tumor Seed Implantation- a Preliminary Study

Contact Info

Product

Resources

About